Background
Methods/design
Objectives
Primary endpoint
Secondary endpoints
-
1. Compare patient-reported GI symptoms using the EPIC questionnaire at the end of RT and 3, 6, 12, and 60 months from end of treatment.
-
2. Compare patient-reported GU symptoms using the EPIC questionnaire at the end of RT and 3, 6, 12, and 60 months from end of treatment.
-
3. Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).
-
4. Compare freedom from biochemical failure (FFBF) and TTP rates with an alternate PSA ≥ PSA nadir + 2 ng/mL definition of BF.
-
5. Compare local failure, regional failure, salvage therapy (i.e., institution of new unplanned anticancer treatment), DM, PCSM, and overall survival (OS) rates.
Inclusion criteria
-
Men aged ≥ 18 with histologically confirmed prostate cancer after prostatectomy with detectable PSA. Patients with detectable post-prostatectomy PSA whether (1) persistently detectable post-operatively or (2) developing biochemical recurrence after prostatectomy (initially undetectable) are eligible. Patients with early BCR or persistently detectable PSA after prostatectomy must wait a minimum of 6 months post-prostatectomy but can initiate ADT as indicated. PSA does not need to be detectable for men with pathologically node positive disease.
-
KPS ≥ 70
-
Patient with no evidence of distant metastatic disease on positron emission tomography (PET)/CT/MRI or bone scan < 90–180 days prior to enrollment. Patients with positive pelvic lymph nodes are eligible.
-
Ability to receive MRI-guided radiotherapy
-
Equivocal evidence of metastatic disease outside the pelvis on standard imaging requires documented negative biopsy
-
Ability to complete the EPIC questionnaire
Exclusion criteria
-
Prior history of receiving pelvic radiotherapy
-
Patients with inflammatory bowel disease
-
Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of ultra-hypofractionated radiotherapy
-
History of bladder neck or urethral disease
Evaluation of randomization and blinding
Interventions
Radiation treatment planning
Organ | Dose (Gy) | BED (Gy) | \({\mathbf{E}\mathbf{Q}\mathbf{D}}_{2}\) | Dose (Gy) | BED (Gy) | \({\mathbf{E}\mathbf{Q}\mathbf{D}}_{2}\) | Dose (Gy) | BED (Gy) | \({\mathbf{E}\mathbf{Q}\mathbf{D}}_{2}\) |
---|---|---|---|---|---|---|---|---|---|
PROSTATIC FOSSA | |||||||||
Comparison of 1.8 Gy × 37 (66.6 Gy) vs. 2.75 Gy × 20 (55 Gy) vs. 6.5 Gy × 5 (32.5 Gy) | |||||||||
Prostate (α/β = 2.7) | 66.6 (1.8 Gy × 37) | 111 | 64 | 55 (2.75 Gy × 20) | 111 | 64 | 32.5 (6.5 Gy × 5) | 111 | 64 |
Bladder (α/β = 3) | 66.6 (1.8 Gy × 37) | 107 | 64 | 55 (2.75 Gy × 20) | 105 | 63 | 32.5 (6.5 Gy × 5) | 103 | 62 |
Rectum (α/β = 5) | 66.6 (1.8 Gy × 37) | 91 | 65 | 55 (2.75 Gy × 20) | 85 | 61 | 32.5 (6.5 Gy × 5) | 75 | 53 |
PELVIC LYMPH NODES | |||||||||
Comparison of 1.8 Gy × 25 (45 Gy) vs. 5.1 Gy × 20 (42 Gy) vs. 5.1 Gy × 5 (25.5 Gy) | |||||||||
Prostate (α/β = 2.7) | 45 (1.8 Gy × 25) | 75 | 43 | 42 (2.1 Gy × 20) | 75 | 43 | 25.5 (5.1 Gy × 20) | 74 | 42 |
Trial Procedures
-
Informed consent
-
Demographics/medical history
-
Physical exam
-
Vital signs, height, weight
-
Post-prostatectomy PSA
-
Pelvic MRI
-
Bone or PET scan
-
Prostate 22-gene test
-
Urodynamic testing (optional)
-
EPIC
-
International Prostate Symptom Score (IPSS)
-
European Quality of Life 5 Dimension (EQ-5D)
-
Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)
-
Whole blood, serum, plasma
-
EPIC
-
IPSS
-
EQ-5D
-
CTCAE v5.0
-
Whole blood, serum, plasma
-
EPIC
-
IPSS
-
EQ-5D
-
CTCAE v5.0
-
Physical exam
-
Post-prostatectomy PSA
-
EPIC
-
IPSS
-
EQ-5D
-
CTCAE v5.0
-
Physical exam
-
Vital signs, height, weight
-
Post-prostatectomy PSA
-
Urodynamic testing (optional)
-
EPIC
-
IPSS
-
EQ-5D
-
CTCAE v5.0
-
Physical exam
-
Vital signs, height, weight
-
Post-prostatectomy PSA
-
Urodynamic testing (optional)
-
EPIC
-
IPSS
-
EQ-5D
-
CTCAE v5.0
Procedure | Screening | First Day of RT | Last Day of RT | FUP at 3mo post-RT | FUP at 6/12/18mo post-RT | FUP at 36/48/60mo post-RT |
---|---|---|---|---|---|---|
Informed Consent | X | |||||
Demographics/Medical History | X | |||||
Physical Exam | X | X | X | X | ||
VS, Height, Weight | X | X | X | X | ||
Post-Prostatectomy PSA | X | X | X | X | ||
Pelvic MRI | X | |||||
Bone or PET Scan | X | |||||
Prostate 22-Gene Test | X | |||||
Whole Blood, Serum, Plasma | X | X | ||||
Urodynamic Testing (optional) | X | X | X | |||
EPIC | X | X | X | X | X | X |
IPSS | X | X | X | X | X | X |
EQ-5D | X | X | X | X | X | X |
CTCAE v5.0 | X | X | X | X | X | X |
Definition of disease assessments
-
Biochemical failure: two definitions of biochemical failure will be assessed:
-
◦ Primary: PSA ≥ 0.4 ng/mL and rising or initiation of salvage hormones
-
◦ Alternate: PSA ≥ PSA nadir + 2 ng/mL where nadir is the lowest post-RT PSA level
-
-
Local failure: development of a new biopsy-proven mass in the prostate bed, after enrollment in the protocol
-
Regional failure: radiographic evidence (CT or MRI) of lymphadenopathy within the pelvis (lymph node size ≥ 1.5 cm in the short axis) in a patient without the diagnosis of a hematologic/lymphomatous disorder associated with adenopathy
-
Distant metastases: radiographic evidence of hematogenous spread (e.g., bone scan, CT, MRI)
-
Progression: first occurrence of biochemical failure, local failure, regional failure, distant metastasis, initiation of salvage ADT
Duration of follow Up
Statistical analysis
Sample size and accrual
Data analysis
-
Secondary safety endpoints: Between treatment arms differences in each safety endpoints measured as change in domain specific EPIC scores at a specific time points (i.e., end of RT, 3, 6, 12, 24, and 60 months) from base line will be evaluated using t-test or Wilcoxon rank sum test whichever is more appropriate. The domain specific EPIC scores measured over time will also be modeled using a linear mixed effects model with fixed effects including time points, treatment arm, Gleason score, baseline PSA, T-stage, age, race, and a random intercept. Between treatment arms differences in GI and GU EPIC scores at 2 years adjusting for baseline scores and other covariates will be assessed using analysis of covariance (ANCOVA). Results from the primary unadjusted analysis and covariates adjusted analysis are expected to lead to similar conclusions. Otherwise, further investigation concerning possible heterogeneous subgroup effects and/or the impacts of missing values will be carried out to ensure that meaningful conclusions can be made.
-
Secondary efficacy endpoints: For competing-risk endpoints such as PCSM, local failure (LF), regional failure (RF), TTP, and DM, Gray’s cumulative incidence method will be used with death as a competing risk for LF, RF and DM and death not due to prostate cancer for PCSM and TTP. OS and FFBF will be estimated by the Kaplan–Meier method and compared between arms with the log-rank test. Cox regression will be used to obtain hazard ratios (HRs) for OS and TTP. Fine and Gray’s regression will be used for the endpoints with competing risks. Adjusted HRs and the respective 95% confidence interval will be computed. Baseline PSA, stratification variables (baseline EPIC score and ADT status), age, race, and other covariates (Gleason, T-stage), will be adjusted for as appropriate in this analysis.